Pazopanib

91 interactions 6 explained in plain English
Also sold as: Votrient Votrient®
About Pazopanib

Pazopanib is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the cells of the kidneys) in adults. Pazopanib is in a class of medications called kinase inhibitors. It works by slowing or stopping the spread of cancer cells. Read the full Pazopanib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Inotuzumab Ozogamicin Injection Histrelin Implant Octreotide Lenvatinib Granisetron Transdermal Patch
1 Contraindicated 85 Major 5 Moderate
All (91) Contraindicated (1) Major (85) Moderate (5)

Major

Pazopanib Omeprazole Gastrobim Explained Reduction in pazopanib bioavailability Details Pazopanib Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Pazopanib Sertraline Explained An increased risk of QT interval prolongation Details Pazopanib Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Pazopanib Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Pazopanib Simvastatin Flolipid Explained Increased risk of ALT elevation Details Pazopanib Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Pazopanib Arsenic Trioxide Trisenox Increased risk of QT interval prolongation Details Pazopanib Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Pazopanib Arsenic Trioxide Injection Trisenox Increased risk of QT interval prolongation Details Pazopanib Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Pazopanib Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Pazopanib Azathioprine Azasan An increased risk of hepatotoxicity Details Pazopanib Azithromycin AzaSite An increased risk of QT interval prolongation Details Pazopanib Alfuzosin UroXatral An increased risk of QT interval prolongation Details Pazopanib Anagrelide Agrylin An increased risk of QT-interval prolongation Details Pazopanib Bedaquiline Sirturo Increased risk of QT interval prolongation Details Pazopanib Chloroquine Aralen® An increased risk of QT interval prolongation Details Pazopanib Cyclosporine Injection Atopica Increased cycloSPORINE plasma concentrations and risk of cycloSPORINE toxicity Details Pazopanib Cyclosporine Ophthalmic Cequa Increased cycloSPORINE plasma concentrations and risk of cycloSPORINE toxicity Details Pazopanib Dasatinib Phyrago An increased risk of QT interval prolongation Details Pazopanib Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Pazopanib Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Pazopanib Dexlansoprazole Dexilant Reduction in pazopanib bioavailability Details Pazopanib Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine concentrations and risk of ergot toxicity Details Pazopanib Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine concentrations and risk of ergot toxicity Details Pazopanib Disopyramide Norpace Increased risk of QT interval prolongation Details Pazopanib Dofetilide Tikosyn Increased dofetilide exposure and an increased risk of QT interval prolongation Details Pazopanib Dolasetron Anzemet An increased risk of QT interval prolongation Details Pazopanib Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Pazopanib Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Pazopanib Encorafenib Braftovi Increased risk of QT interval prolongation Details Pazopanib Entrectinib Rozlytrek An increased risk of QT interval prolongation Details Pazopanib Eribulin Injection Halaven An increased risk of QT-interval prolongation Details Pazopanib Esomeprazole Nexium Reduction in pazopanib bioavailability Details Pazopanib Esomeprazole Injection Nexium Reduction in pazopanib bioavailability Details Pazopanib Famotidine Calmicid An increased risk of QT-interval prolongation; decreased pazopanib bioavailability Details Pazopanib Famotidine Injection Calmicid An increased risk of QT-interval prolongation; decreased pazopanib bioavailability Details Pazopanib Felbamate Felbatol An increased risk of QT-interval prolongation Details Pazopanib Fentanyl Transdermal Patch Duragesic® Increased fentanyl plasma concentrations and risk of fentanyl toxicity Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.